Richard F Little1. 1. Head, Blood and AIDS-related Cancer Therapeutics, Clinical Investigations Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
PURPOSE OF REVIEW: The era of modern HIV therapeutics is well underway. The cancer and infectious disease epidemiology of HIV disease has markedly altered as populations are availed to the benefits of antiretroviral therapy (ARV). The types of cancers occurring among those with HIV infection has broadened but the case burden in absolute numbers is very low relative to the background population. There are fewer incident cases of the AIDS-defining cancers (aggressive B-cell lymphomas, Kaposi's sarcoma, and cervical cancer). There is an increased risk for certain non-AIDS-defining cancers, but these occur somewhat sporadically relative to clinical trial enrollment. The changing epidemiology of cancer in HIV poses challenges as well as opportunities for participation of persons with HIV in cancer therapy clinical trials. RECENT FINDINGS: There are excellent examples of cancer trials that inform cancer therapy for patients with HIV infection. Examples include those from HIV-specific trials and from trials mainly focused on the background population that included patients with HIV infection. SUMMARY: Interpretation of clinical trials to guide therapy for those with HIV infection and cancer largely depends on data that does not include HIV-infected patients. The ability to extend clinical trial findings to populations not included in clinical trials remains problematic for a variety of populations, including those with HIV or AIDS. Careful prioritization of studies designed to bridge this gap is needed. However, there are published studies that serve as excellent examples bridging these gaps and the portfolio of cancer therapy trials underway will inform HIV and cancer better than at any time in the past.
PURPOSE OF REVIEW: The era of modern HIV therapeutics is well underway. The cancer and infectious disease epidemiology of HIV disease has markedly altered as populations are availed to the benefits of antiretroviral therapy (ARV). The types of cancers occurring among those with HIV infection has broadened but the case burden in absolute numbers is very low relative to the background population. There are fewer incident cases of the AIDS-defining cancers (aggressive B-cell lymphomas, Kaposi's sarcoma, and cervical cancer). There is an increased risk for certain non-AIDS-defining cancers, but these occur somewhat sporadically relative to clinical trial enrollment. The changing epidemiology of cancer in HIV poses challenges as well as opportunities for participation of persons with HIV in cancer therapy clinical trials. RECENT FINDINGS: There are excellent examples of cancer trials that inform cancer therapy for patients with HIV infection. Examples include those from HIV-specific trials and from trials mainly focused on the background population that included patients with HIV infection. SUMMARY: Interpretation of clinical trials to guide therapy for those with HIV infection and cancer largely depends on data that does not include HIV-infectedpatients. The ability to extend clinical trial findings to populations not included in clinical trials remains problematic for a variety of populations, including those with HIV or AIDS. Careful prioritization of studies designed to bridge this gap is needed. However, there are published studies that serve as excellent examples bridging these gaps and the portfolio of cancer therapy trials underway will inform HIV and cancer better than at any time in the past.
Authors: Thomas S Uldrick; Victoria Wang; Deirdre O'Mahony; Karen Aleman; Kathleen M Wyvill; Vickie Marshall; Seth M Steinberg; Stefania Pittaluga; Irina Maric; Denise Whitby; Giovanna Tosato; Richard F Little; Robert Yarchoan Journal: Clin Infect Dis Date: 2010-08-01 Impact factor: 9.079
Authors: Frits van Rhee; Raymond S Wong; Nikhil Munshi; Jean-Francois Rossi; Xiao-Yan Ke; Alexander Fosså; David Simpson; Marcelo Capra; Ting Liu; Ruey Kuen Hsieh; Yeow Tee Goh; Jun Zhu; Seok-Goo Cho; Hanyun Ren; James Cavet; Rajesh Bandekar; Margaret Rothman; Thomas A Puchalski; Manjula Reddy; Helgi van de Velde; Jessica Vermeulen; Corey Casper Journal: Lancet Oncol Date: 2014-07-17 Impact factor: 41.316
Authors: Thomas S Uldrick; Mark N Polizzotto; Karen Aleman; Deirdre O'Mahony; Kathleen M Wyvill; Victoria Wang; Vickie Marshall; Stefania Pittaluga; Seth M Steinberg; Giovanna Tosato; Denise Whitby; Richard F Little; Robert Yarchoan Journal: Blood Date: 2011-04-12 Impact factor: 22.113
Authors: Thomas S Uldrick; Mark N Polizzotto; Karen Aleman; Kathleen M Wyvill; Vickie Marshall; Denise Whitby; Victoria Wang; Stefania Pittaluga; Deirdre O'Mahony; Seth M Steinberg; Richard F Little; Robert Yarchoan Journal: Blood Date: 2014-10-20 Impact factor: 22.113
Authors: Michelle A Rudek; Cathy Y Chang; Kenneth Steadman; Michael D Johnson; Naveen Desai; John F Deeken Journal: Cancer Chemother Pharmacol Date: 2014-02-02 Impact factor: 3.333
Authors: Oliver W Press; Hongli Li; Heiko Schöder; David J Straus; Craig H Moskowitz; Michael LeBlanc; Lisa M Rimsza; Nancy L Bartlett; Andrew M Evens; Erik S Mittra; Ann S LaCasce; John W Sweetenham; Paul M Barr; Michelle A Fanale; Michael V Knopp; Ariela Noy; Eric D Hsi; James R Cook; Mary Jo Lechowicz; Randy D Gascoyne; John P Leonard; Brad S Kahl; Bruce D Cheson; Richard I Fisher; Jonathan W Friedberg Journal: J Clin Oncol Date: 2016-04-11 Impact factor: 44.544
Authors: Joseph C Alvarnas; Jennifer Le Rademacher; Yanli Wang; Richard F Little; Gorgun Akpek; Ernesto Ayala; Steven Devine; Robert Baiocchi; Gerard Lozanski; Lawrence Kaplan; Ariela Noy; Uday Popat; Jack Hsu; Lawrence E Morris; Jason Thompson; Mary M Horowitz; Adam Mendizabal; Alexandra Levine; Amrita Krishnan; Stephen J Forman; Willis H Navarro; Richard Ambinder Journal: Blood Date: 2016-06-13 Impact factor: 22.113
Authors: Michelle A Rudek; Page C Moore; Ronald T Mitsuyasu; Bruce J Dezube; David Aboulafia; John Gerecitano; Ryan Sullivan; Mary E Cianfrocca; David H Henry; Lee Ratner; Missak Haigentz; Afshin Dowlati; Richard F Little; Susan Percy Ivy; John F Deeken Journal: Cancer Date: 2014-01-28 Impact factor: 6.860
Authors: Kieron Dunleavy; Stefania Pittaluga; Margaret Shovlin; Seth M Steinberg; Diane Cole; Cliona Grant; Brigitte Widemann; Louis M Staudt; Elaine S Jaffe; Richard F Little; Wyndham H Wilson Journal: N Engl J Med Date: 2013-11-14 Impact factor: 91.245
Authors: Steven Habbous; Helen Guo; Jaclyn Beca; Wei Fang Dai; Wanrudee Isaranuwatchai; Matthew Cheung; Kelvin K W Chan Journal: Cancer Med Date: 2020-08-13 Impact factor: 4.452